SHINE Medical Technologies has partnered with Czech Academy of Sciences to use its method of Lutetium production and is poised to become the second supplier in the United States. Lu-177 is currently being used to treat certain cancers and is in research to learn if the isotope can be used to treat other types. Lu-177 is a beta and gamma emitter with a half-life of approximately 6.5 days making the isotope ideal for therapies. SHINE expects to produce Lu-177 by irradiating ytterbium-176 (not to be confused with yttrium) making it a pure and concentrated isotope with no long-lived metastable elements.
Leave a Reply